Researchers found that combining a new treatment called INBRX-106 with Merck’s Keytruda significantly improved response rates in patients with advanced head and neck cancer. In a mid-phase clinical trial, the combination therapy achieved an objective response rate (ORR) of 44%, compared to just 21.4% for Keytruda alone. This means that nearly half of the patients receiving both treatments saw a reduction in their tumors, which is a promising outcome for those battling this aggressive form of cancer.

This discovery is particularly relevant for individuals diagnosed with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC), especially those with high PD-L1 expression. If you or someone you know is facing this diagnosis, these findings suggest that combination therapies may offer a more effective treatment option, potentially leading to better tumor shrinkage and improved overall outcomes.

The trial involved 68 participants and is part of a larger study called HexAgon, which is still ongoing. While the results are encouraging, it’s important to note that this is a mid-phase trial, meaning that further research is needed to confirm these benefits in larger populations. Inhibrx plans to expand its research, including starting a phase 3 trial and exploring other cancer types, which could further validate the effectiveness of INBRX-106.

For those interested in the latest cancer treatments, staying informed about ongoing clinical trials and emerging therapies could be beneficial. If you or a loved one is considering treatment options, discussing participation in clinical trials with a healthcare provider may provide access to cutting-edge therapies.

Source: fiercebiotech.com